Liminal BioSciences Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Liminal BioSciences Inc.
Pharma and the US biotech will target key regulators of cellular metabolism with focus on immune and neurological disorders. Royalty Pharma buys portion of PTC’s royalty rights to risdiplam, under development at Roche.
The latest drug development news and highlights from our US FDA Performance Tracker.
CBER’s novel biologic approvals in 2018 were few, long, and with a low level of innovation. But the center’s work to build regulatory framework for emerging technologies is setting the stage for a different story in 2019.
FDA’s approval teams cleared a total of 65 new molecular entities and novel biologics in 2018, blowing past previous records. Scrip looks at how that breaks down for industry leaders.
- Research, Analytical Equipment & Supplies
- Large Molecule
- Synthesis Technologies, Production Processes
Drug Discovery Tools
- Other Names / Subsidiaries
- Bioniche Life Sciences Inc.
- Fairhaven Pharmaceuticals Inc.
- Innovon Life Sciences Holdings Limited.
- NantPro BioSciences, LLC
- ProMetic BioTherapeutics
- Prometic ChinaCo
- Prometic Life Sciences Inc.
- Telesta Therapeutics Inc.